Medaphor Group PLC Launch of new Point-of-Care Ultrasound simulator (2028F)
February 19 2018 - 1:00AM
UK Regulatory
TIDMMED
RNS Number : 2028F
Medaphor Group PLC
19 February 2018
MedaPhor Group plc
("MedaPhor" or the "Group" or the "Company")
Launch of new Point-of-Care Ultrasound simulator
MedaPhor Group plc (AIM: MED), the intelligent ultrasound
software and simulation company, announces the launch of its new
BodyWorks Eve simulator platform, an ultra-realistic manikin-based
simulator to train medical professionals practising Point-of-Care
Ultrasound (PoCUS) across emergency medicine and critical care.
First revealed at the International Meeting on Simulation in
Healthcare (IMSH) in Los Angeles last month and now launched for
general sale, the BodyWorks Eve is believed to be the first
hi-fidelity female manikin-based simulator for emergency PoCUS
training.
BodyWorks Eve combines the normal and pathological hearts from
MedaPhor's HeartWorks simulator with the complete upper chest to
pelvis real patient scans from MedaPhor's ScanTrainer platform to
teach the requirements of the growing PoCUS skills market, as
outlined by the International Federation of Emergency Medicine
(IFEM). Complete with over 100 real patient ultrasound cases and
over 10,000 patient scenario combinations, BodyWorks Eve replicates
learning in a real-life emergency or critical care setting,
allowing the tutor to control and change the severity and pathology
of the patient in real-time.
MedaPhor has partnered with Lifecast Body Simulation
("Lifecast"), who have developed a range of accurate and lifelike
'bodies' for medical training, to increase the realism of the
BodyWorks Eve simulator. Lifecast supplies the ultra-realistic
manikin, which combines with MedaPhor's intelligent ultrasound
simulation technology.
Stuart Gall, Chief Executive Officer at MedaPhor, comments:
"Point-of-Care ultrasound, whilst transforming the front line in
emergency medicine and critical care, presents a huge challenge for
the global medical industry in terms of upskilling the workforce.
BodyWorks Eve is designed to meet these specific PoCUS training
requirements and help universities, colleges and hospitals bridge
the training gap to deliver positive outcomes for patients.
"We believe Eve can become the gold standard for global PoCUS
ultrasound training and is a superb addition to the existing
ScanTrainer and HeartWorks simulator range, transforming patient
care through comprehensive and flexible learning platforms."
Enquiries:
MedaPhor Group plc www.investors.medaphor.com
Stuart Gall, CEO Tel: +44 (0)29 2075
Ian Whittaker, COO 6534
Cenkos Securities Tel: +44 (0)20 7397
8900
Camilla Hume/Bobbie Hilliam
(Nominated Advisor)
Michael Johnson / Julian
Morse (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or
medaphor@walbrookpr.com
Paul McManus / Anna Mob: +44 (0)7980 541 893 / Mob:
Dunphy +44 (0)7876 741 001
About MedaPhor (www.investors.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and
simulation company, develops artificial intelligence-based clinical
image analysis software tools, augmented reality-based needle
guidance software and advanced hi-fidelity haptic and manikin-based
training simulators for medical practitioners.
Based in Cardiff and Oxford in the UK and Atlanta in the US,
MedaPhor is split into two divisions:
Intelligent Ultrasound Simulation and Training
Focuses on hi-fidelity ultrasound education and training through
simulation. Its two main products are the ScanTrainer OBGYN and
General Medical simulator training platform and the HeartWorks
echocardiography simulator platform. Over 500 MedaPhor simulators
have been sold to over 300 medical institutions in over 30
countries around the world.
Intelligent Ultrasound Clinical Support
Focuses on augmented reality and deep-learning based algorithms
to make ultrasound machines smarter and more accessible. Products
in development include ScanNav which uses machine-learning based
algorithms to automatically identify and grade ultrasound images to
provide scan assessment and audit of obstetric scanning.
NeedleGuide aims to simplify ultrasound-guided needling by using
deep learning and augmented reality to provide the user with
pathway guidance and automated tracking for a range of medical
procedures.
Some products in the pipeline may require US FDA approval, as
such this material should be considered informational only and does
not constitute an offer to sell, or infer claims or benefits.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBSGDDLXBBGII
(END) Dow Jones Newswires
February 19, 2018 02:00 ET (07:00 GMT)
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From Jul 2023 to Jul 2024